Sunshine Biopharma heads into its May 20 earnings event in the grip of one of the sharpest short-selling acceleration episodes its lending market has seen in over a year.
The positioning story is stark. Short interest has exploded nearly 5.3x in one week, from roughly 94,000 shares to 528,000, pushing the short interest as a percentage of free float to 10.8%. That pace of accumulation is the real signal — not the absolute level, but the velocity. Borrow availability has collapsed in lockstep: it stood above 1,000% as recently as May 12, meaning shares were plentiful to borrow. By May 15, availability had crashed to just 3.3% — the tightest reading in the past year, with barely one share remaining for every thirty already lent out. Cost to borrow held around 17.4%, elevated but not extreme, and largely unchanged on the week — suggesting the squeeze in availability is demand-driven rather than a supply-side disruption.
The price action tells the same story from the other side. The stock closed at $0.28 on May 15, down 73% on the week and 71% over the past month. That collapse is not new: on May 13, the stock fell 55% in a single session following what appears to have been a news-driven event, before short interest began building aggressively into the May 20 date. The ORTEX short score has surged accordingly — from 46 two weeks ago to 80.1 on May 15, placing the stock in the 4th percentile by short score rank across the full universe, meaning almost every other stock in the database carries less short pressure.
Analyst data for SBFM is too stale to carry weight — the most recent change on record is a reiteration from Aegis Capital in October 2025, and the mean price target of $5.60 bears no credible relationship to the current $0.28 stock price. The EV figure is deeply negative, reflecting a pre-revenue clinical-stage company burning cash. Institutional ownership is thin: L1 Global Manager holds roughly 6.5% of shares, and the second-largest disclosed holder is David Natan with a 2% position initiated as recently as April 14. No insider activity since early 2024 is on record.
Peer context offers modest perspective: TLSI and ATYR are each down roughly 40-47% on the week, suggesting sector-wide stress in micro-cap biotech, but SBFM's decline is still several multiples more severe. The print tomorrow will test whether there is any fundamental news capable of reversing a short position that has grown nearly six-fold in five trading days, with the lending pool now effectively closed.
See the live data behind this article on ORTEX.
Open SBFM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
